
By Jay Somaney: On Saturday, the Board of Directors made the surprising announcement that Infosys ( INFY ) co-founder NR Narayana Murthy was returning to the company as Chairman of the Board, replacing K V Kamath, who will become lead independent
INFY ) joins the trend of bringing back previously successful managers to try to revive its fortunes, appointing co-founder NR Narayana Murthy as Executive Chairman to replace Kundapur Vaman Kamath. Infosys has struggled since Murthy stepped down as Chairman
Medium 34,275 1 Westn Digtl WDC 2 None 60.46 1.26 High 14,633 1 PPG PPG 2 Narrow 158.84 1.38 High 23,137 1 Ciena CIEN NR - 16.35 - - 1,693 1 Stock Price and Morningstar Rating data as of 05-17-13. We don't normally go into much detail on
DECK , DLB , ELY , EMN , EXPE , FII , FR , FSL , GERN , IGT , IM , INAP , INFA , KBR , KEG , KLAC , LEG , MCRS , MXIM , N , NR , NTGR , OLN , PFG , PKI , PMCS , QLIK , RMD , RRC , RSG , SBUX , SIMO , SPN , SWKS , SYNA , TCO , THRX , TLAB , UHS , VPRT
DECK , DLB , ELY , EMN , EXPE , FII , FR , FSL , GERN , IGT , IM , INAP , INFA , KBR , KEG , KLAC , LEG , MCRS , MXIM , N , NR , NTGR , OLN , PFG , PKI , PMCS , QLIK , RMD , RRC , RSG , SBUX , SIMO , SPN , SWKS , SYNA , TCO , THRX , TLAB , UHS , VPRT
Credit Rating AA-), Vertex Pharmaceuticals (8%; BBB), Beth Israel Deaconess Medical Center (6%; NR ), Regeneron Pharmaceuticals (6%; NR ), Elan Pharmaceuticals (6%; BB-) and Sanofi (4%; AA-). BioMed recently derived 18% of its
basis "remain stable" showing the consumer "remains in the sluggish but stable trajectory." In a separate report, Northcoast Research upgrades the shares to Buy from Neutral. Price targets are now $360 for CS and $400 for NR . 1 comment!
acquisitions or returns to shareholders with its inflated cash position. We have also seen companies, such as Smith & Nephew SNN ( NR ), with its acquisition of Healthpoint, quickly reduce balance sheet cash to make acquisitions that could boost growth prospects
Newpark Resources ( NR ): Q4 EPS of $0.17 in-line. Revenue of $270M (+4% Y/Y) beats by $17.92M . ( PR ) Post your comment!
LONDON, Jan 29 (Reuters) - * Nr investments ltd - bumi proposal fails to deal with key issue * Nr investments (nri): bumi "separation" proposal leaves our company in the